The development of ataxia telangiectasia mutated kinase inhibitors

Area of Science:

• Molecular Biology
• Oncology
• Drug Discovery

Background:

• Cancer therapies like radiation and genotoxic drugs are often ineffective due to cancer cell DNA repair mechanisms, leading to resistance.
• DNA damage response (DDR) pathways, involving kinases ATM, ATR, and DNA-PK, are crucial for regulating cellular responses to DNA breaks (DSBs and SSBs).
• Targeting these DDR kinases presents a therapeutic strategy to enhance cancer treatment efficacy.

Purpose of the Study:

• To review the development of selective inhibitors targeting ATM (ataxia telangiectasia mutated) kinase.
• To explore inhibitors that target ATM as part of a broader strategy.
• To highlight the potential of these inhibitors in sensitizing cancer cells to therapy and exploiting synthetic lethality.

Main Methods:

• Literature review focusing on the development and targets of ATM inhibitors.
• Analysis of kinase inhibitors involved in DNA damage response pathways.
• Discussion of the concept of synthetic lethality in cancer treatment.

Main Results:

• ATM, ATR, and DNA-PK are key kinases in DNA damage response pathways.
• Inhibitors of ATM, ATR, and DNA-PK can sensitize cancer cells to radiation and chemotherapy.
• Selective inhibitors offer potential for targeted cancer cell killing via synthetic lethality, though few are currently identified.

Conclusions:

• Selective ATM inhibitors and other kinase inhibitors targeting ATM are crucial for overcoming therapeutic resistance in cancer.
• These inhibitors hold promise for enhancing current cancer treatment strategies and achieving selective cancer cell death.
• Further development of selective inhibitors is needed to fully realize their therapeutic potential.